Mubadala snaps up UCB’s neurology, allergy business in China for USD 680 mn
Mubadala aims to grow Chinese UCB’s central nervous system offerings
Available in your choice of English or Arabic
Mubadala aims to grow Chinese UCB’s central nervous system offerings
Plus: More from Masdar, EGA, MBRIF, Bajaj, Lucid, Adani, and DP World
ADQ, Mubadala, and Emirates Investment Authority are sizing up Misr Pharma and CID
Something went wrong. Please refresh the page and/or try again.
Queue